Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 28, 2026, 12:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Placebo (for sarilumab) Clear all

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 56
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more

Conditions: Uveitis
Interventions: Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab); Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more

Conditions: Giant Cell Arteritis
Interventions: Sarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Boca Raton, Florida • Gainesville, Florida • Iowa City, Iowa + 3 more

Conditions: Sarcoidosis
Interventions: Sarilumab, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Polymyalgia Rheumatica
Interventions: Sarilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 43
States / cities: Avondale, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Ankylosing Spondylitis
Interventions: Sarilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 26
States / cities: Birmingham, Alabama • Anaheim, California • Los Angeles, California + 23 more

Conditions: COVID-19
Interventions: Sarilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 62
States / cities: Los Angeles, California • Sacramento, California • Santa Monica, California + 42 more

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Adalimumab, Placebo (for sarilumab), Placebo (for adalimumab); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 17
States / cities: Covina, California • Long Beach, California • Whittier, California + 14 more

Conditions: Indolent Systemic Mastocytosis
Interventions: sarilumab, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Polymyalgia Rheumatica
Interventions: Sarilumab SAR153191 (REGN88), Sarilumab-matching placebo, Prednisone, Prednisone-matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 10
States / cities: Upland, California • Denver, Colorado • Stamford, Connecticut + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 30
States / cities: Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Placebo, Golimumab, methotrexate (MTX), Folic/folinic acid; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Placebo (for sarilumab), Methotrexate, Folic Acid; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 45
States / cities: Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 39 more

Conditions: Rheumatoid Arthritis
Interventions: sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more

Search by objective public record fields.

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)